Trial Profile
A Phase I/II Study of Pembrolizumab in Combination With Nab-Paclitaxel in Patients With Unresectable Stage III or Stage IV Non-Small Cell Lung Carcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 12 Feb 2021 Status changed from active, no longer recruiting to completed.
- 19 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Mar 2017 Status changed from not yet recruiting to recruiting.